FDA Inspection
Eli Lilly & CompanyEli Lilly & Company – FDA Inspection, Apr 23, 2018
Record Details
This FDA Inspection record concerns Eli Lilly & Company, with an inspection on April 23, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · fe9a1bb2-4f91-45e7-959f-e3d4cea0855c
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1049177
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 314.80(c)(2)Late submission of quarterly safety reports
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Eli Lilly & Company
35| Date | Classification | Office | Project area |
|---|---|---|---|
| January 9, 2026 | NAI | Bioresearch Monitoring | |
| May 20, 2025 | VAI | Detroit District Office | Drug Quality Assurance |
| March 27, 2025 | Not classified | Detroit District Office | |
| January 15, 2025 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| October 6, 2023 | Not classified | Detroit District Office |
Other documents for Eli Lilly & Company
- FDA Inspection 1298628 - 2026-01-09
- FDA Inspection 1270621 - 2025-05-20
- FDA Inspection 1260339 - 2025-03-27
- FDA Inspection 1229895 - 2025-01-15
- FDA Inspection 1220489 - 2023-10-06
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.